The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 11, 1999, Pages 1535-1542

  Sykes, A P ^a   Bhogal, R ^b   Brampton, C ^a   Chander, C ^c   Whelan, C ^a   Parsons, M E ^a   Bird, J ^b  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b Chiroscience Ltd   (United Kingdom)

^c UNIVERSITY OF BEDFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MYELOPEROXIDASE; SALAZOSULFAPYRIDINE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; DRUG BIOAVAILABILITY; HISTOLOGY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; COLITIS; HYDROXAMIC ACIDS; INFLAMMATORY BOWEL DISEASES; MALE; MATRIX METALLOPROTEINASES; PEROXIDASE; PROTEASE INHIBITORS; RATS; RATS, WISTAR; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032722533     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00633.x     Document Type: Article

References (19)

1. 1 Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997; 15: 61-75.
2. 2 Puolakkainen P, Vaalamo M, Karjalainen-Lindsberg M-L, Kere J, Kivilaakso F, Saarialho-Kere U. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (HME, MMP-12) and TIMP-3 in intestinal ulcerations. Gastroenterology 1998; 114: G4358 (Abstract).
3. 3 Talbot DC, Brown PD. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 1996; 32A: 2528-33.
4. 4 Pender SLF, Tickle SP, Docherty AJP, Howie D, Wathen NC, MacDonald TT. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 1997; 158: 1582-90.
5. 5 Puolakkainen P, Karjalainen-Lindsberg M-L, Vaalamo M, Airola T, Kivilaakso E, Saarialhokere U. Expression of matrix metalloproteinases (MMPs) in peptic-ulcers and in inflammatory bowel-disease. Gastroenterology 1995; 108: A197 (Abstract).
6. 6 Foegh P, Saermak T, Bingham A, Brynskov J. TNFα converting enzyme (TACE) mRNA expression in colonic mucosal specimens from patients with IBD. Gastroenterology 1998; 114: G4004 (Abstract).
7. 7 Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989; 96: 795-803.
8. 8 Zingarelli B, Squadrito F, Graziani P, Camerini R, Caputi AP. Effects of zileuton, a new 5-lipoxygenase inhibitor in experimentally induced colitis in rats. Agents Actions 1993; 39: 150-6.
9. 9 Bradley PP, Priebat DA, Christensen RD, Rothstein G, Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982; 78: 206-9.
10. 10 Knight CG, Willenbrock F, Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS 1992; 296: 263-6.
11. 11 Stotland BR, Lichtenstein GR. Newer treatments for inflammatory bowel disease. Primary Care 1996; 23: 577-608.
12. 12 Morphy JR, Millican TA, Porter JR. Matrix metalloproteinase inhibitors: Current status. Current Med Chem 1995; 2: 743-62.
13. 13 Hoult JRS, Moore PK. Effects of sulphasalazine and its metabolites on prostuglundin synthesis, inactivation and actions on smooth muscle. Br J Pharmacol 1980; 68: 719-30.
14. 14 Ahnfelt-Ronne I, Haagen Nielson O. The anti-inflammatory moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger. Agents Actions 1987; 21: 191-4.
15. 15 Hodgson J. Remodelling MMPIs. Biotechnology 1995; 13: 554-7.
16. 16 Gronberg A, Isaksson P, Smedegard G. Inhibitory effect of sulfasalazine on production of IL-1β, IL-6 and TNFα. Arthritis Rheum 1994; 37: S383.
17. 17 Denis LJ, Verwij J. Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest New Drugs 1997; 15: 175-85.
18. 18 Hooper NM, Karran EH, Turner AJ. Membrane protein secretases. Biochem J 1997; 321: 265-79.
19. 19 Cawston TE. Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol Ther 1996; 70: 163-82.